Legato Capital Management LLC Grows Stock Position in Repligen Corporation $RGEN

Legato Capital Management LLC raised its position in Repligen Corporation (NASDAQ:RGEN) by 31.9% in the 3rd quarter, Holdings Channel reports. The fund owned 21,100 shares of the biotechnology company’s stock after purchasing an additional 5,100 shares during the period. Legato Capital Management LLC’s holdings in Repligen were worth $2,820,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in RGEN. Hantz Financial Services Inc. boosted its stake in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the period. CWM LLC lifted its holdings in Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after buying an additional 135 shares in the last quarter. Trust Co. of Vermont purchased a new position in Repligen in the 3rd quarter valued at about $67,000. Wilmington Savings Fund Society FSB grew its stake in shares of Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 495 shares in the last quarter. Finally, UMB Bank n.a. increased its position in shares of Repligen by 17.0% during the third quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 97 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares in the company, valued at $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on RGEN shares. Wells Fargo & Company cut their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a report on Saturday. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. UBS Group decreased their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Finally, Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Stock Performance

Repligen stock opened at $124.97 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $175.77. The company has a fifty day moving average price of $153.37 and a two-hundred day moving average price of $147.10. The company has a market cap of $7.03 billion, a PE ratio of 147.02, a P/E/G ratio of 2.50 and a beta of 1.15.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. During the same period last year, the firm posted $0.44 EPS. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.